| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $6.9M | -23.2% |
| R&D Expense | $177.3M | +36.9% |
| SG&A Expense | $43.8M | +32.8% |
| Operating Income | -$224.1M | +26.7% |
| Income Tax | $0 | — |
| Net Income | -$212.4M | +27.5% |
| EPS (Basic) | -$2.43 | +51.4% |
| EPS (Diluted) | -$2.43 | +51.4% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $653.5M | +355.9% |
| Current Assets | $660.8M | +198.5% |
| Total Assets | $683.2M | +184.4% |
| Current Liabilities | $45.0M | -17.2% |
| Total Liabilities | $48.8M | -17.3% |
| Stockholders' Equity | $634.3M | +250.1% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$190.9M | -72.3% |
| Capital Expenditures | $9.7M | +35.0% |
| Investing Cash Flow | $60.8M | +171.5% |
| Financing Cash Flow | $640.4M | +166.2% |
| Free Cash Flow | -$200.6M | -70.1% |